Logo.png
Moderate to Severe Plaque Psoriasis Pipeline Review | Clinical Trial Analysis by DelveInsight
April 19, 2022 13:00 ET | DelveInsight Business Research LLP
New York, USA, April 19, 2022 (GLOBE NEWSWIRE) -- Moderate to Severe Plaque Psoriasis Pipeline Review | Clinical Trial Analysis by DelveInsight Plaque Psoriasis is the most common type of psoriasis...
Arcutis logo.png
Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting
March 25, 2022 07:30 ET | Arcutis Biotherapeutics, Inc.
Pooled analysis of DERMIS-1 and DERMIS-2 demonstrated significantly more roflumilast-treated patients achieved Investigator Global Assessment (IGA) success (40%) at week 8 compared to vehicle (7%),...
Coherus BioSciences, Inc. logo
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
December 20, 2021 07:59 ET | Coherus BioSciences, Inc.
- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) - - YUSIMRY is Coherus' second FDA-approved product - REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE...
Zai Lab logo .png
ZL-1102, Zai Lab’s Internally Developed Novel Human VH Antibody Fragment, Achieved Proof of Concept in Phase 1b Psoriasis Study
October 20, 2021 16:05 ET | Zai Lab Limited
Topical therapy with ZL-1102 resulted in clinical improvement in local PASI score, erythema and scaling, target lesion size, and responder rates in patients with mild-to-moderate chronic plaque...
KINIKSA _2c_final - Copy.jpg
Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus
May 11, 2020 07:30 ET | Kiniksa Pharmaceuticals, Ltd.
– Mavrilimumab treatment protocol in patients with severe COVID-19 pneumonia and hyperinflammation showed improved clinical outcomes compared to matched contemporaneous controls, including earlier...
Reports and Data.jpeg-01
Psoriasis Drugs Market To Reach USD 39.00 Billion By 2027 | Reports And Data
January 22, 2020 08:52 ET | Reports and Data
New York, Jan. 22, 2020 (GLOBE NEWSWIRE) -- The global psoriasis drugs market is forecast to reach USD 39.00 Billion by 2027, according to a new report by Reports and Data. Psoriasis can be defined...
Dermira_Logo_RGB_R4V2_M01.jpg
Newly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
June 26, 2017 07:30 ET | Dermira, Inc.
MENLO PARK, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Announces Appointment of Ian Clements as Vice President, Investor Relations
June 06, 2017 07:30 ET | Dermira, Inc.
MENLO PARK, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira to Present at Jefferies 2017 Global Healthcare Conference
May 30, 2017 16:05 ET | Dermira, Inc.
MENLO PARK, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Announces Closing of 3.00% Convertible Senior Notes Offering
May 16, 2017 16:01 ET | Dermira, Inc.
MENLO PARK, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the closing of its previously announced offering of 3.00% Convertible Senior Notes due 2022 (the...